Effects of a putative antidepressant with a rapid onset of action in defeated mice with different coping strategies

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 2, 2012, Pages 317-327

  Gómez Lázaro, Eneritz ^a   Garmendia, Larraitz ^a   Beitia, Garikoitz ^a   Perez Tejada, Joana ^a   Azpiroz, Arantza ^a   Arregi, Amaia ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Coping strategies in social defeat; FST; Glucocorticoid receptors; RS 67333; Serotonergic receptors

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; CORTICOSTERONE; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; SEROTONIN 1A RECEPTOR; SEROTONIN 4 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN LEVEL; CHRONIC STRESS; CONTROLLED STUDY; COPING BEHAVIOR; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION PROFILING; HYPOTHALAMUS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSIOLOGICAL PROCESS; SOCIAL ADAPTATION; SOCIAL STRESS; STRESS MANAGEMENT;

ADAPTATION, PSYCHOLOGICAL; ANILINE COMPOUNDS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CORTICOSTERONE; DOMINANCE-SUBORDINATION; HYPOTHALAMUS; INTERLEUKIN-6; MALE; MICE; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, GLUCOCORTICOID; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SPLEEN; STRESS, PSYCHOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862855189     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.019     Document Type: Article

References (82)

1. Antonijevic I.A. Depressive disorders - is it time to endorse different pathophysiologies?. Psychoneuroendocrinology 2006, 31:1-15.
2. Avitsur R., Padgett D.A., Dhabhar F.S., Stark J.L., Kramer K.A., Engler H., et al. Expression of glucocorticoid resistance following social stress requires a second signal. J Leukoc Biol 2003, 74:507-513.
3. Bailey M.T., Kinsey S.G., Padgett D.A., Sheridan J.F., Leblebicioglu B. Social stress enhances IL-1beta and TNF-alpha production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells. Physiol Behav 2009, 98:351-358.
4. Bartolomucci A., Palanza P., Sacerdote P., Panerai A.E., Sgoifo A., Dantzer R., et al. Social factors and individual vulnerability to chronic stress exposure. Neurosci Biobehav Rev 2005, 29:67-81.
5. Beitia G., Garmendia L., Azpiroz A., Vegas O., Brain P.F., Arregi A. Time-dependent behavioral, neurochemical, and immune consequences of repeated experiences of social defeat stress in male mice and the ameliorative effects of fluoxetine. Brain Behav Immun 2005, 19:530-539.
6. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
7. Bijak M., Tokarski K., Maj J. Repeated treatment with antidepressant drugs induces subsensitivity to the excitatory effect of 5-HT4 receptor activation in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1997, 355:14-19.
8. Bijak M., Zahorodna A., Tokarski K. Opposite effects of antidepressants and corticosterone on the sensitivity of hippocampal CA1 neurons to 5-HT1A and 5-HT4 receptor activation. Naunyn Schmiedebergs Arch Pharmacol 2001, 363:491-498.
9. Binder E.B., Kunzel H.E., Nickel T., Kern N., Pfennig A., Majer M., et al. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 2009, 34:99-109.
10. Blanchard D.C., Spencer R.L., Weiss S.M., Blanchard R.J., McEwen B., Sakai R.R. Visible burrow system as a model of chronic social stress: behavioral and neuroendocrine correlates. Psychoneuroendocrinology 1995, 20:117-134.
11. Blier P., De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994, 15:220-226.
12. Brain P.F., McAllister K.H., Walmsley S.V. Drug effects on social behavior: methods in ethopharmacology. Neuromethods 1989, 687-739. The Humana Press Inc., Totowa, NJ. A.A. Boulton, G.B. Baker, A.J. Greenshaw (Eds.).
13. Buwalda B., De Boer S.F., Schmidt E.D., Felszeghy K., Nyakas C., Sgoifo A., et al. Long-lasting deficient dexamethasone suppression of hypothalamic-pituitary-adrenocortical activation following peripheral CRF challenge in socially defeated rats. J Neuroendocrinol 1999, 11:513-520.
14. Buwalda B., Felszeghy K., Horvath K.M., Nyakas C., De Boer S.F., Bohus B., et al. Temporal and spatial dynamics of corticosteroid receptor down-regulation in rat brain following social defeat. Physiol Behav 2001, 72:349-354.
15. Carvalho L.A., Pariante C.M. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress 2008, 11:411-424.
16. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
17. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967, 113:1237-1264.
18. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005, 4:775-790.
19. Cryan J.F., Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 2004, 9:326-357.
20. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
21. De Kloet E.R., Vreugdenhil E., Oitzl M.S., Jöels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998, 19:269-301.
22. DeBattista C., Belanoff J., Glass S., Khan A., Horne R.L., Blasey C., et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006, 60:1343-1349.
23. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
24. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
25. Duarte F.S., Andrade Eda S., Vieira R.A., Uieara M., Nunes R.J., De Lima T.C. Synthesis and antidepressant-like action of stereoisomers of imidobenzenesulfonylaziridines in mice evaluated in the forced swimming test. Bioorg Med Chem 2006, 14:5397-5401.
26. Duman R.S. A silver bullet for the treatment of depression?. Neuron 2007, 55:679-681.
27. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
28. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:445-450.
29. Flores B.H., Kenna H., Keller J., Solvason H.B., Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006, 31:628-636.
30. Fries E., Hesse J., Hellhammer J., Hellhammer D.H. A new view on hypocortisolism. Psychoneuroendocrinology 2005, 30:1010-1016.
31. Gold P.W., Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002, 7:254-275.
32. Golde W.T., Gollobin P., Rodriguez L.L. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim 2005, 34:39-43.
33. Gómez-Lázaro E., Arregi A., Beitia G., Vegas O., Azpiroz A., Garmendia L. Individual differences in chronically defeated male mice: behavioral, endocrine, immune, and neurotrophic changes as markers of vulnerability to the effects of stress. Stress 2011, 14:537-548.
34. Gupta S., Aslakson E., Gurbaxani B.M., Vernon S.D. Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability. Theor Biol Med Model 2007, 4:8.
35. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
36. Hellhammer D.H., Wade S. Endocrine correlates of stress vulnerability. Psychother Psychosom 1993, 60:8-17.
37. Heuser I.J., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., et al. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 1996, 153:93-99.
38. Hirschfeld R.M. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000, 61(Suppl. 6):4-6.
39. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
40. Hunter A.J., Nolan P.M., Brown S.D. Towards new models of disease and physiology in the neurosciences: the role of induced and naturally occurring mutations. Hum Mol Genet 2000, 9:893-900.
41. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?. Biol Psychiatry 2007, 62:47-54.
42. Koolhaas J.M., Korte S.M., De Boer S.F., Van der Vegt B.J., Van Reenen C.G., Hopster H., et al. Coping styles in animals: current status in behavior and stress-physiology. Neurosci Biobehav Rev 1999, 23:925-935.
43. Kubera M., Lin A.H., Kenis G., Bosmans E., van Bockstaele D., Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001, 21:199-206.
44. Kubera M., Basta-Kaim A., Budziszewska B., Rogoz Z., Skuza G., Leskiewicz M., et al. Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. Int J Neuropsychopharmacol 2006, 9:297-305.
45. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:744-759.
46. Kudryavtseva N.N., Bakshtanovskaya I.V., Koryakina L.A. Social model of depression in mice of C57BL/6J strain. Pharmacol Biochem Behav 1991, 38:315-320.
47. Lanni C., Govoni S., Lucchelli A., Boselli C. Depression and antidepressants: molecular and cellular aspects. Cell Mol Life Sci 2009, 66:2985-3008.
48. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
49. Licht C.L., Knudsen G.M., Sharp T. Effects of the 5-HT(4) receptor agonist RS67333 and paroxetine on hippocampal extracellular 5-HT levels. Neurosci Lett 2010, 476:58-61.
50. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
51. Lopez-Duran N.L., Kovacs M., George C.J. Hypothalamic-pituitary-adrenal axis dysregulation in depressed children and adolescents: a meta-analysis. Psychoneuroendocrinology 2009, 34:1272-1283.
52. Lucas G., Debonnel G. 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur J Neurosci 2002, 16:817-822.
53. Lucas G., Compan V., Charnay Y., Neve R.L., Nestler E.J., Bockaert J., et al. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry 2005, 57:918-925.
54. Lucas G., Rymar V.V., Du J., Mnie-Filali O., Bisgaard C., Manta S., et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007, 55:712-725.
55. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Psychopharmacology: the fourth generation of progress 1995, 933-944. Raven Press, New York. F. Bloom, D. Kupfer (Eds.).
56. Mason B.L., Pariante C.M. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect 2006, 19:603-608.
57. Mukherjee K., Knisely A., Jacobson L. Partial glucocorticoid agonist-like effects of imipramine on hypothalamic-pituitary-adrenocortical activity, thymus weight, and hippocampal glucocorticoid receptors in male C57BL/6 mice. Endocrinology 2004, 145:4185-4191.
58. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002, 52:503-528.
59. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007, 41:326-331.
60. O'Connor J.C., Andre C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009, 29:4200-4209.
61. Okugawa G., Omori K., Suzukawa J., Fujiseki Y., Kinoshita T., Inagaki C. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol 1999, 11:887-895.
62. Pariante C.M., Thomas S.A., Lovestone S., Makoff A., Kerwin R.W. Do antidepressants regulate how cortisol affects the brain?. Psychoneuroendocrinology 2004, 29:423-447.
63. Pascual-Brazo J., Castro E., Diaz A., Valdizan E.M., Pilar-Cuellar F., Vidar R., et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 dayerrs) administration of the 5-HT4 receptor agonist RS67333. Int J Neuropsychopharmacol 2011, 1-13.
64. Peiffer A., Veilleux S., Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 1991, 16:505-515.
65. Pepin M.C., Beaulieu S., Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 1989, 6:77-83.
66. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
67. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010, 15:393-403.
68. Reul J.M., Stec I., Söder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993, 133:312-320.
69. Ribeiro S.C., Tandon R., Grunhaus L., Greden J.F. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993, 150:1618-1629.
70. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122:509-522.
71. Shen Y., Connor T.J., Nolan Y., Kelly J.P., Leonard B.E. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 1999, 65:1773-1786.
72. Stark J.L., Avitsur R., Padgett D.A., Campbell K.A., Beck F.M., Sheridan J.F. Social stress induces glucocorticoid resistance in macrophages. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1799-R1805.
73. Tamburella A., Micale V., Navarria A., Drago F. Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1205-1210.
74. Van Praag H.M. Can stress cause depression?. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:891-907.
75. Veenema A.H., Meijer O.C., De Kloet E.R., Koolhaas J.M., Bohus B.G. Differences in basal and stress-induced HPA regulation of wild house mice selected for high and low aggression. Horm Behav 2003, 43:197-204.
76. Vidal R., Valdizan E.M., Mostany R., Pazos A., Castro E. Long-term treatment with fluoxetine induces desensitization of 5-HT4 receptor-dependent signalling and functionality in rat brain. J Neurochem 2009, 110:1120-1127.
77. Wohleb E.S., Hanke M.L., Corona A.W., Powell N.D., Stiner L.M., Bailey M.T., et al. β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci 2011, 31:6277-6288.
78. Wu J., Du J., Xu C., Le J., Xu Y., Liu B., et al. Icariin attenuates social defeat-induced down-regulation of glucocorticoid receptor in mice. Pharmacol Biochem Behav 2011, 98:273-278.
79. Yau J.L., Noble J., Hibberd C., Seckl J.R. Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 2001, 306(3):161-164.
80. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. Mineralocorticoid receptor function in major depresión. Arch Gen Psychiatry 2003, 60:24-28.
81. Young A.H., Gallagher P., Watson S., Del-Estal D., Owen B.M., Ferrier I.N. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004, 29:1538-1545.
82. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.